{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"267"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"355"}],"units":"Participants"}],"description":"Overall MRD-negativity rate was defined as the percentage of participants in the ITT population who achieved both MRD-negativity by NGS (at or below a sensitivity threshold of 10-5) in bone marrow aspirate and a CR or better response at any time after the date of randomization (and prior to disease progression, receipt of subsequent therapy, or both).","groups":[{"description":"Arm A: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.","id":"OG000","title":"Velcade Lenalidomide Dexamethasone (VRd)"},{"description":"Arm B: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with subcutaneous daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by subcutaneous daratumumab in combination with lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.","id":"OG001","title":"Daratumumab + VRd (D-VRd)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Randomized population, intention-to-treat","reportingStatus":"POSTED","timeFrame":"From randomization to the clinical cutoff date. Maximum follow up was 54.41 months.","title":"Overall MRD Negativity Rate","type":"SECONDARY","unitOfMeasure":"Participants"}